Mantle Cell Lymphoma An Issue Of Hematology Oncology Clinics Of North America Volume 34 5

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton’s Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin’s Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin’s Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin’s lymphoma; and Targeting biology in non-Hodgkin’s lymphoma.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Jonathan W. Friedberg, is devoted to Follicular Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Articles in this important issue include: Epidemiology of Follicular Lymphoma, Pathogenesis of Follicular Lymphoma, Circulating tumor DNA and MRD assessment in Follicular Lymphoma, Clinical and biological prognostic factors in Follicular Lymphoma, Vitamin D and Follicular Lymphoma, Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma, Initial Treatment of High Tumor Burden Follicular Lymphoma, Maintenance Antibody Therapy of Follicular Lymphoma, Cellular Therapy in Follicular Lymphoma, Immunomodulatory Agents in Follicular Lymphoma, Phosphoinositide 3-Kinase Inhibition in Follicular Lymphoma, Novel Agents Beyond Immunomodulatory Imide Drugs and Phosphoinositide 3-Kinases for Follicular Lymphoma, Early progression of Follicular Lymphoma, Biological Basis of Histological Transformation, and Treatment of Histological Transformation.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin's Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin's Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin's lymphoma; and Targeting biology in non-Hodgkin's lymphoma.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Jonathan W. Friedberg, is devoted to Follicular Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Articles in this important issue include: Epidemiology of Follicular Lymphoma, Pathogenesis of Follicular Lymphoma, Circulating tumor DNA and MRD assessment in Follicular Lymphoma, Clinical and biological prognostic factors in Follicular Lymphoma, Vitamin D and Follicular Lymphoma, Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma, Initial Treatment of High Tumor Burden Follicular Lymphoma, Maintenance Antibody Therapy of Follicular Lymphoma, Cellular Therapy in Follicular Lymphoma, Immunomodulatory Agents in Follicular Lymphoma, Phosphoinositide 3-Kinase Inhibition in Follicular Lymphoma, Novel Agents Beyond Immunomodulatory Imide Drugs and Phosphoinositide 3-Kinases for Follicular Lymphoma, Early progression of Follicular Lymphoma, Biological Basis of Histological Transformation, and Treatment of Histological Transformation.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

Practical and clinically focused, Abeloff’s Clinical Oncology is a trusted medical reference book designed to capture the latest scientific discoveries and their implications for cancer diagnosis and management of cancer in the most accessible manner possible. Abeloff’s equips everyone involved - from radiologists and oncologists to surgeons and nurses - to collaborate effectively and provide the best possible cancer care. Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability. Select the most appropriate tests and imaging studies for cancer diagnosis and staging of each type of cancer, and manage your patients in the most effective way possible by using all of the latest techniques and approaches in oncology. Enhance your understanding of complex concepts with a color art program that highlights key points and illustrates relevant scientific and clinical problems. Stay at the forefront of the latest developments in cancer pharmacology, oncology and healthcare policy, survivorship in cancer, and many other timely topics. See how the most recent cancer research applies to practice through an increased emphasis on the relevance of new scientific discoveries and modalities within disease chapters. Streamline clinical decision making with abundant new treatment and diagnostic algorithms as well as concrete management recommendations. Take advantage of the collective wisdom of preeminent multidisciplinary experts in the field of oncology, including previous Abeloff’s editors John E. Niederhuber, James O. Armitage, and Michael B. Kastan as well as new editors James H. Doroshow from the National Cancer Institute and Joel E. Tepper of Gunderson & Tepper: Clinical Radiation Oncology. Quickly and effortlessly access the key information you need with the help of an even more user-friendly, streamlined format. Access the complete contents anytime, anywhere at Expert Consult, and test your mastery of the latest knowledge with 500 online multiple-choice review questions.